Kalshi, AppliedXL, and biopharma prediction markets

Kalshi operates regulated prediction markets on biopharma outcomes, such as clinical trial readouts and FDA regulatory decisions. AppliedXL serves as the resolution infrastructure for these markets: our systems monitor public institutional records and assess, with evidence, whether a contract’s conditions have been met. Read the announcement.

Drug-development odds are among the most valuable and least visible numbers in the economy. Estimates exist inside banks, expert networks, and pharma companies, but they stay private, and roughly 30% of trials required to report results have posted none. A public contract produces a continuously updated probability anyone can read.

Events with verifiable public outcomes: regulatory approval decisions, trial readouts, and similar milestones documented in official records.

AppliedXL collaborates with Kalshi, but Kalshi makes the listing decisions. Members of the public can submit market suggestions through the Kalshi website.

They isolate a single question. Public equities force a position on the whole business at once: management, cash, pipeline, macro. A contract prices the science or the regulatory outcome on its own terms.

No. AppliedXL does not provide investment, legal, or medical advice, and none of its data, probabilities, or resolutions is a recommendation to trade any contract or security. All of it is provided for informational purposes only. Prediction-market prices and probability estimates are aggregated or modeled expectations, not statements of fact about any drug, trial, or company.

Every prediction market contract must eventually settle as yes or no. Resolution infrastructure is the layer that makes that determination: continuous monitoring of primary sources, matching official disclosures to contract language, and producing an auditable record of why a market settled the way it did. This capability is described on the Resolution page.

Biopharma outcomes are buried in dense regulatory filings, trial registries, and agency announcements. A trial can hit its endpoint while the drug still fails approval. Resolving these markets correctly requires domain expertise and systematic monitoring of the primary record, not headlines.

Each contract names a specific public document as its resolution source before trading opens: the registered primary endpoint on ClinicalTrials.gov, the FDA approval letter, or the advisory committee vote record. AppliedXL’s systems monitor those sources continuously, flag disclosures relevant to open contracts, and match them against the contract’s precise terms. Outcomes are determined by independent public artifacts, not sponsor communications or analyst interpretation. Hard cases get human review, and every resolution carries an audit trail back to the source documents. See a worked example: How a Fact Becomes a Settlement.

Resolution borrows its discipline from journalism: the process replicates a newsroom’s fact-checking workflow, accelerated with technology but with a human in the loop for final adjudication on both the AppliedXL and Kalshi sides. No contract settles on a machine reading alone, and the people overseeing adjudication have backgrounds in biology and biopharma. Resolution draws only on publicly disclosed information, never patient-level or other nonpublic data.

Kalshi operates the markets and holds regulatory responsibility for settlement. AppliedXL provides the evidence and determinations that inform resolution, with a documented trail supporting each one.

They are two different kinds of number. AppliedXL’s probability of success is our own probability model, derived exclusively from clinical, regulatory, and operational data. Kalshi’s odds are the live market price: an aggregate of what traders with money at stake collectively believe, updating continuously as they trade. One is model-driven; the other is market-driven.

Yes, and we treat these questions as central rather than an afterthought. We consulted a wide range of experts in developing the markets, including clinicians, academics, bioethicists, biopharma R&D and strategy professionals, and investors, and set out the opportunities alongside the risks in our joint industry report with Kalshi. The safeguards follow from that work: contracts are scoped to late-stage trials with publicly registered endpoints, listed only after enrollment closes so a market can’t affect recruitment, and resolved against named institutional documents rather than sentiment. Curation guidelines govern which markets are appropriate to list in the first place, and we continue to engage experts and patient communities as the markets develop.

The markets were designed to reduce that risk. Contracts cover late-stage trials with publicly registered endpoints, and markets are listed only after enrollment closes, so that a visible price is less likely to affect patients' decisions to enroll or physicians' decisions to refer.

Kalshi requires employment verification for all traders in these markets as an added integrity measure, and its standard prohibition on trading with material nonpublic information applies in full.

No. AppliedXL employees are prohibited from participating in prediction markets entirely, company-wide, not just on contracts we help resolve.

Kalshi is a federally regulated exchange in the United States, and these contracts are offered under that framework. Questions about the regulatory treatment of event contracts are directed to Kalshi.

No. AppliedXL is an information company for the age of AI, a computational journalism lab building the public-record intelligence layer for regulated sectors. Prediction market resolution is one application of that capability; the same infrastructure powers products across other regulated domains.

Yes. Biopharma is the first vertical, but the underlying capability, turning public institutional records into verified outcomes, extends to other regulated domains.

Yes. AppliedXL works with subject-matter experts, newsrooms, and academics who can contribute domain expertise or data to the resolution process.

For the latest trial and regulatory news alongside resolution updates, see Biopharma News or the AppliedXL platform. Kalshi and AppliedXL have also published a joint industry report, Biopharma’s Public Probability: The State and Future of Prediction Markets in Drug Development, and a step-by-step walkthrough of one market settling: How a Fact Becomes a Settlement.